期刊
AMERICAN JOURNAL OF ROENTGENOLOGY
卷 207, 期 2, 页码 266-273出版社
AMER ROENTGEN RAY SOC
DOI: 10.2214/AJR.16.16181
关键词
cancer; contrast medium; fluorescence; multimodality imaging; PET
资金
- NIH from the National Institute of Biomedical Imaging and Bioengineering [4R00EB013904-03]
OBJECTIVE. The purpose of this article is to summarize advances in PET fluorescence resolution, agent design, and preclinical imaging that make a growing case for clinical PET fluorescence imaging. CONCLUSION. Existing SPECT, PET, fluorescence, and MRI contrast imaging techniques are already deeply integrated into the management of cancer, from initial diagnosis to the observation and management of metastases. Combined positron-emitting fluorescent contrast agents can convey new or substantial benefits that improve on these proven clinical contrast agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据